SCHEMBL3380993

SCHEMBL3380993

NC(=O)c1ccc(Cc2ccccc2)c(C(=O)N2CCOC(c3ccccc3)C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBTD1 Q05BQ5 1/20 0.40
L3MBTL3 Q96JM7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCD O00767 1/20 0.39
KRAS P01116 3/20 0.39
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
TYK2 P29597 2/20 0.39
JAK3 P52333 2/20 0.39
USP30 Q70CQ3 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PARP14 Q460N5 1/20 0.39
PARP10 Q53GL7 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PLA2G10 O15496 1/20 0.38
PLA2G2A P14555 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379273 0.83 ALDH1A1 (0.54) MBTD1L3MBTL3L3MBTL1JAK2JAK1
SCHEMBL3379828 0.82 PARP14 (0.53) MBTD1L3MBTL3L3MBTL1SCDPARP14
SCHEMBL14413642 0.74 USP30 (0.54) L3MBTL1SCDUSP30MEN1KMT2A
SCHEMBL1710753 0.73 USP30 (0.50) L3MBTL1USP30MEN1KMT2ANPC1
SCHEMBL3378150 0.73 PDE2A (0.34) SCDKRASMEN1KMT2ANAMPT
SCHEMBL3377190 0.72 NAMPT (0.47) MBTD1L3MBTL3L3MBTL1MEN1KMT2A
SCHEMBL918049 0.72 USP30 (0.42) USP30MEN1KMT2APARP14PARP10
SCHEMBL1710855 0.72 SLC6A7 (0.53) L3MBTL1USP30MEN1KMT2AKDM4E
SCHEMBL20394937 0.72 ALDH1A1 (0.51) USP30MEN1KMT2ARAB9AALDH1A1
SCHEMBL3377139 0.71 SMN1; SMN2 (0.56) L3MBTL1MEN1KMT2APARP14PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MBTD1 3581/4885L3MBTL3 1732/4885L3MBTL1 1040/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 MBTD1 4414/4885L3MBTL3 2893/4885L3MBTL1 3199/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MBTD1 3581/4885L3MBTL3 1732/4885L3MBTL1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.